Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics

Core Insights - Jazz Pharmaceuticals reported revenue of $1.05 billion for the quarter ended September 2024, marking an 8.5% increase year-over-year, with an EPS of $6.61 compared to $4.84 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $1.04 billion by 1.75%, and the EPS surpassed the consensus estimate of $5.47 by 20.84% [1] Revenue Performance - Product sales, net reached $989.71 million, exceeding the average estimate of $976.01 million by analysts, representing a year-over-year increase of 5.5% [3] - Total revenues from Oncology products, specifically Defitelio/defibrotide, were $65.82 million, significantly above the average estimate of $48.66 million, reflecting a 37.9% year-over-year increase [3] - Neuroscience revenue from Oxybate (Xywav) was $388.47 million, surpassing the average estimate of $381.21 million, with a year-over-year growth of 17.1% [3] - Total revenues from Epidiolex/Epidyolex amounted to $251.56 million, slightly above the average estimate of $248.26 million, showing a 17.7% increase year-over-year [3] - Sativex revenues were $4.59 million, below the estimated $5.79 million, indicating a slight decline of 0.9% year-over-year [3] - Total Neuroscience revenues reached $702.72 million, exceeding the average estimate of $685.35 million, with a year-over-year increase of 4.1% [3] - Total Oncology revenues were $284.75 million, slightly below the average estimate of $286.96 million, reflecting a 9.4% year-over-year increase [3] - Rylaze revenues were $98.78 million, below the average estimate of $113.81 million, showing a decline of 5.8% year-over-year [3] - Vyxeos revenues reached $34.31 million, exceeding the average estimate of $38.27 million, with a year-over-year increase of 15% [3] - Zepzelca revenues were $85.84 million, slightly below the average estimate of $86.22 million, reflecting a year-over-year increase of 10.1% [3] - Other revenues were $2.23 million, below the estimated $3.16 million, indicating a significant decline of 23.3% year-over-year [3] Stock Performance - Jazz Pharmaceuticals' shares have returned 3.5% over the past month, outperforming the Zacks S&P 500 composite, which returned 0.7% [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]